Targeting the MHC class II pathway of antigen presentation enhances immunogenicity and safety of allergen immunotherapy
Authors:
Abstract
Background: Current s.c. allergen‐specific immunotherapy (SIT) leads to amelioration of IgE‐mediated allergy, but it requires numerous allergen injections over several years and is frequently associated with severe side‐effects. The aim of this study was to test whether modified recombinant allergens can improve therapeutic efficacy in SIT while reducing allergic side‐effects.Methods: The major cat allergen Fel d 1 was fused to a TAT‐derived protein translocation domain and to a truncated invariant chain for targeting the MHC class II pathway (MAT‐Fel d 1). The immunogenicity was evaluated in mice, while potential safety issues were assessed by cellular antigen stimulation test (CAST) using basophils from cat‐dander‐allergic patients.Results: MAT‐Fel d 1 enhanced induction of Fel d 1‐specific IgG2a antibody responses as well as the secretion of IFN‐γ and IL‐2 from T cells. Subcutaneous allergen‐specific immunotherapy of mice using the modified Fel d 1 provided stronger protection against anaphylaxis than SIT with unmodified Fel d 1, and MAT‐Fel d 1 caused less degranulation of human basophils than native Fel d 1.Conclusion: MAT‐Fel d 1 allergen enhanced protective antibody and Th1 responses in mice, while reducing human basophil degranulation. Immunotherapy using MAT‐Fel d 1 allergen therefore has the potential to enhance SIT efficacy and safety, thus, shortening SIT. This should increase patient compliance and lower treatment costs.Keywords
This publication has 32 references indexed in Scilit:
- Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranesProceedings of the National Academy of Sciences, 2007
- Effect of grass pollen immunotherapy with Alutard SQ® on quality of life in seasonal allergic rhinoconjunctivitisAllergy, 2007
- Chemical Modification of Birch Allergen Extract Leads to a Reduction in Allergenicity as well as ImmunogenicityInternational Archives of Allergy and Immunology, 2007
- Design, engineering and in vitro evaluation of MHC class‐II targeting allergy vaccinesAllergy, 2007
- Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccinesExpert Opinion on Biological Therapy, 2006
- Heat denaturation, a simple method to improve the immunotherapeutic potential of allergensEuropean Journal of Immunology, 2005
- Rational design of hypoallergens applied to the major cat allergen Fel d 1Clinical & Experimental Allergy, 2005
- Transcellular protein transduction using the Tat protein of HIV-1Advanced Drug Delivery Reviews, 2005
- Mechanisms of immunotherapyJournal of Allergy and Clinical Immunology, 2004
- Clinical efficacy and safety of a depigmented and glutaraldehyde polymerized therapeutic vaccine of Parietaria judaicaAllergologia et Immunopathologia, 2003